Moderna company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
Investors pushed Moderna’s stock higher on Thursday, pointing to an FDA advisory panel review of the company’s influenza vaccine application tied to its mRNA technology platform.
THE APEX TIMES
THE APEX TIMES
The biotech said Dr. Stephen Hoge will take on expanded operational oversight across several franchise areas, including infectious disease, intismeran and rare disease, as the company prepares its next wave of launches.
THE APEX TIMES
Moderna’s stock jumped about 9% in the afternoon session after traders moved ahead of a pivotal FDA advisory committee meeting tied to the company’s mRNA seasonal flu vaccine program.
THE APEX TIMES
Moderna’s shares jumped after a Yahoo Finance report said newly posted FDA materials appeared to point toward approval for the company’s mRNA-based influenza vaccine.
THE APEX TIMES
A fresh round of market chatter highlighted SpaceX’s sharp run-up, alongside other widely tracked names such as Western Digital and Moderna, underscoring how investors are rotating across sectors rather than following a single theme.
THE APEX TIMES
Moderna (MRNA) is trading around $49.64 after a recent rebound, with returns showing a mixed pattern over the past week and month. Analysts and traders watching the tape are now weighing whether the stock’s bounce has pushed it above what fundamentals would justify.
THE APEX TIMES
With COVID-19 revenues falling, Moderna is under pressure to prove that its mRNA platform can translate into durable, profitable products. A new market debate centers on whether the company needs to generate profits immediately, or whether it can justify continued investment in the pipeline and manufacturing.
THE APEX TIMES
The investigational cancer vaccine, designed to prime the immune system against early precancerous growths, is set to open in spring or summer 2026 after UK ethics approval.
THE APEX TIMES
A UBS note highlighted Moderna’s (MRNA) near-term clinical catalysts, including a Phase III melanoma interim analysis expected later in 2026.
